<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01918371</url>
  </required_header>
  <id_info>
    <org_study_id>GMA-OZU-13-598</org_study_id>
    <nct_id>NCT01918371</nct_id>
  </id_info>
  <brief_title>A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective data review study will evaluate anti-VEGF injections for retinal vein
      occlusion (RVO) or diabetic macular edema (DME).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 2</measure>
    <time_frame>Up to Time of Injection 2 (Up to 4 Years)</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 3</measure>
    <time_frame>Up to Time of Injection 3 (Up to 4 Years)</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 4</measure>
    <time_frame>Up to Time of Injection 4 (Up to 4 Years)</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 5</measure>
    <time_frame>Up to Time of Injection 5 (Up to 4 Years)</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 6</measure>
    <time_frame>Up to Time of Injection 6 (Up to 4 Years)</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 7</measure>
    <time_frame>Up to Time of Injection 7 (Up to 4 Years)</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 8</measure>
    <time_frame>Up to Time of Injection 8 (Up to 4 Years)</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 9</measure>
    <time_frame>Up to Time of Injection 9 (Up to 4 Years)</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 10</measure>
    <time_frame>Up to Time of Injection 10 (Up to 4 Years)</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 11</measure>
    <time_frame>Up to Time of Injection 11 (Up to 4 Years)</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With BCVA of 20/40 or Better in the Study Eye</measure>
    <time_frame>Up to 4 Years</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</measure>
    <time_frame>Up to 4 Years</time_frame>
    <description>CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Both BCVA 20/40 or Better or CRT ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</measure>
    <time_frame>Up to 4 Years</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BCVA in the Study Eye</measure>
    <time_frame>UP to 4 Years</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in BCVA in the Study Eye</measure>
    <time_frame>Baseline, Up to 4 Years</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Increase From Baseline of ≥2 Lines in BCVA in the Study Eye</measure>
    <time_frame>Baseline, Up to 4 Years</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). An increase of 2 or more lines read correctly from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Increase From Baseline of ≥3 Lines in BCVA in the Study Eye</measure>
    <time_frame>Baseline, Up to 4 Years</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). An increase of 3 or more lines read correctly from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CRT by OCT in the Study Eye</measure>
    <time_frame>Baseline, Up to 4 Years</time_frame>
    <description>CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement of ≥2 Lines in BCVA in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <description>Kaplan-Meier estimates of the time in months to improvement of ≥2 lines in BCVA. BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement of ≥3 Lines in BCVA in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <description>Kaplan-Meier estimates of the time in months to improvement of ≥3 lines in BCVA. BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement in BCVA to 20/40 or Better in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <description>Kaplan-Meier estimates of the time to Improvement in months in BCVA to 20/40 or Better. BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <description>Kaplan-Meier estimates of the time to improvement in months in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement to Both 20/40 or Better in BCVA and Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <description>Kaplan-Meier estimates of the time to improvement to Both 20/40 or Better in BCVA and Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT. BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Between Anti-VEGF Injections in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <description>The mean time in months between anti-VEGF Injections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Intravitreal Anti-VEGF Injections in the Study Eye</measure>
    <time_frame>0-6 Months, 7-12 Months, Years 1,2,3</time_frame>
    <description>To be included in the time period analysis, patients must have been enrolled on the study for at least a minimum of 0 weeks, 24 weeks, 50 weeks, 100 weeks, and 150 weeks, respectively, and must have received at least 1 injection during that time period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Switching to a Second or Third Anti-VEGF Agent After First Injection in the Study Eye</measure>
    <time_frame>UP to 4 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Switching Among Different Anti-VEGF Agents in the Study Eye</measure>
    <time_frame>Up to 4 Years</time_frame>
    <description>Participants who switched among the different Anti-VEGF Agents: bevacizumab, ranibizumab and aflibercept.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Undergoing Focal Laser Surgery in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Undergoing Panretinal Photocoagulation (PRP) Surgery in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Loss (Decrease) in BCVA of ≥1 Line From Baseline in the Study Eye</measure>
    <time_frame>Baseline, Up to 4 Years</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). A loss of 1 or more lines read correctly from Baseline indicates a worsening of vision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Gain (Increase) in BCVA of ≥1 Line From Baseline in the Study Eye</measure>
    <time_frame>Baseline, Up to 4 Years</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). A gain of 1 or more lines read correctly from Baseline indicates an improvement of vision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With No Change in BCVA From Baseline in the Study Eye</measure>
    <time_frame>Baseline, Up to 4 Years</time_frame>
    <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Undergoing Glaucoma Laser Surgery in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Undergoing Incisional Glaucoma Surgery in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Phakic Patients With Cataract Surgery in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <description>Phakic patients have intraocular lens implants.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">323</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Patients with RVO</arm_group_label>
    <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with DME</arm_group_label>
    <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-VEGF</intervention_name>
    <description>Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.</description>
    <arm_group_label>Patients with RVO</arm_group_label>
    <arm_group_label>Patients with DME</arm_group_label>
    <other_name>Avastin®</other_name>
    <other_name>Lucentis®</other_name>
    <other_name>Eylea®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Received Anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema
        (DME)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Macular edema in the study eye due to RVO or DME

          -  Received an anti-VEGF injection in the study eye on or after June 2010 for RVO and on
             or after August 2012 for DME

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2013</study_first_submitted>
  <study_first_submitted_qc>August 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2013</study_first_posted>
  <results_first_submitted>November 25, 2015</results_first_submitted>
  <results_first_submitted_qc>April 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2016</results_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>323 patients were enrolled in the study and were divided into 2 groups based on their diagnosis: 166 patients with Retinal Vein Occlusion and 157 patients with Diabetic Macular Edema. 2 patients (1 in each group) were missing data and are not included in the analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Patients With RVO</title>
          <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
        </group>
        <group group_id="P2">
          <title>Patients With DME</title>
          <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants With Complete Data</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missing Data</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants with data available.</population>
      <group_list>
        <group group_id="B1">
          <title>Patients With RVO</title>
          <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
        </group>
        <group group_id="B2">
          <title>Patients With DME</title>
          <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="165"/>
            <count group_id="B2" value="156"/>
            <count group_id="B3" value="321"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.4" spread="13.62" lower_limit="26" upper_limit="99"/>
                    <measurement group_id="B2" value="63.4" spread="11.29" lower_limit="31" upper_limit="91"/>
                    <measurement group_id="B3" value="66.4" lower_limit="26" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 2</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>Up to Time of Injection 2 (Up to 4 Years)</time_frame>
        <population>All participants with data available up to time of Injection 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 2</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with data available up to time of Injection 2.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.09"/>
                    <measurement group_id="O2" value="16.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 3</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>Up to Time of Injection 3 (Up to 4 Years)</time_frame>
        <population>All participants with data available up to time of Injection 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 3</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with data available up to time of Injection 3.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.81"/>
                    <measurement group_id="O2" value="16.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 4</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>Up to Time of Injection 4 (Up to 4 Years)</time_frame>
        <population>All participants with data available up to time of Injection 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 4</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with data available up to time of Injection 4.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.56"/>
                    <measurement group_id="O2" value="17.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 5</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>Up to Time of Injection 5 (Up to 4 Years)</time_frame>
        <population>All participants with data available up to time of Injection 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 5</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with data available up to time of Injection 5.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.59"/>
                    <measurement group_id="O2" value="22.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 6</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>Up to Time of Injection 6 (Up to 4 Years)</time_frame>
        <population>All participants with data available up to time of Injection 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 6</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with data available up to time of Injection 6.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.47"/>
                    <measurement group_id="O2" value="19.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 7</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>Up to Time of Injection 7 (Up to 4 Years)</time_frame>
        <population>All participants with data available up to time of Injection 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 7</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with data available up to time of Injection 7.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.29"/>
                    <measurement group_id="O2" value="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 8</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>Up to Time of Injection 8 (Up to 4 Years)</time_frame>
        <population>All participants with data available up to time of Injection 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 8</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with data available up to time of Injection 8.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.97"/>
                    <measurement group_id="O2" value="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 9</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>Up to Time of Injection 9 (Up to 4 Years)</time_frame>
        <population>All participants with data available up to time of Injection 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 9</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with data available up to time of Injection 9.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.81"/>
                    <measurement group_id="O2" value="24.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 10</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>Up to Time of Injection 10 (Up to 4 Years)</time_frame>
        <population>All participants with data available up to time of Injection 10.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 10</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with data available up to time of Injection 10.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.57"/>
                    <measurement group_id="O2" value="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 11</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>Up to Time of Injection 11 (Up to 4 Years)</time_frame>
        <population>All participants with data available up to time of Injection 11.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 11</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with data available up to time of Injection 11.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.30"/>
                    <measurement group_id="O2" value="38.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With BCVA of 20/40 or Better in the Study Eye</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly</description>
        <time_frame>Up to 4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With BCVA of 20/40 or Better in the Study Eye</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly</description>
          <population>All participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Time of Injection 2 (n=139,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.24"/>
                    <measurement group_id="O2" value="54.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 3 (n=141,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.19"/>
                    <measurement group_id="O2" value="53.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 4 (n=141,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.35"/>
                    <measurement group_id="O2" value="51.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 5 (n=134,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.72"/>
                    <measurement group_id="O2" value="56.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 6 (n=120,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.50"/>
                    <measurement group_id="O2" value="55.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 7 (n=107,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.60"/>
                    <measurement group_id="O2" value="54.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 8 (n=86,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.51"/>
                    <measurement group_id="O2" value="62.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 9 (n=74,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.70"/>
                    <measurement group_id="O2" value="55.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 10 (n=65,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.08"/>
                    <measurement group_id="O2" value="53.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 11 (n=56,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.64"/>
                    <measurement group_id="O2" value="56.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</title>
        <description>CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>Up to 4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</title>
          <description>CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Time of Injection 2 (n=133,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.38"/>
                    <measurement group_id="O2" value="28.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 3 (n=134,122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.72"/>
                    <measurement group_id="O2" value="26.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 4 (n=145,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.10"/>
                    <measurement group_id="O2" value="29.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 5 (n=137,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.12"/>
                    <measurement group_id="O2" value="33.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 6 (n=115,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.78"/>
                    <measurement group_id="O2" value="33.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 7 (n=104,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.73"/>
                    <measurement group_id="O2" value="31.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 8 (n=85,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.65"/>
                    <measurement group_id="O2" value="27.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 9 (n=74,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.51"/>
                    <measurement group_id="O2" value="31.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 10(n=74,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.57"/>
                    <measurement group_id="O2" value="27.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 11(n=58,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.79"/>
                    <measurement group_id="O2" value="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Both BCVA 20/40 or Better or CRT ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>Up to 4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Both BCVA 20/40 or Better or CRT ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Time of Injection 2 (n=157,147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.06"/>
                    <measurement group_id="O2" value="59.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 3 (n=157,147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.25"/>
                    <measurement group_id="O2" value="57.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 4(n=158,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.52"/>
                    <measurement group_id="O2" value="58.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 5 (n=148,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.68"/>
                    <measurement group_id="O2" value="62.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 6 (n=129,107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.32"/>
                    <measurement group_id="O2" value="63.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 7 (n=115,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.57"/>
                    <measurement group_id="O2" value="60.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 8 (n=94,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.34"/>
                    <measurement group_id="O2" value="60.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 9 (n=84,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.38"/>
                    <measurement group_id="O2" value="58.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 10 (n=76,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.63"/>
                    <measurement group_id="O2" value="54.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 11 (n=61,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.05"/>
                    <measurement group_id="O2" value="60.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BCVA in the Study Eye</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best).</description>
        <time_frame>UP to 4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BCVA in the Study Eye</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best).</description>
          <population>All participants with data available.</population>
          <units>lines</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=133,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="4.04"/>
                    <measurement group_id="O2" value="11.8" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 2 (n=139,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="3.69"/>
                    <measurement group_id="O2" value="12.8" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 3 (n=141,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="3.56"/>
                    <measurement group_id="O2" value="12.9" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 4 (n=141,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="4.09"/>
                    <measurement group_id="O2" value="12.9" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 5 (n=134,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="3.87"/>
                    <measurement group_id="O2" value="13.0" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 6 (n=120,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="3.82"/>
                    <measurement group_id="O2" value="12.9" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 7 (n=107,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="3.97"/>
                    <measurement group_id="O2" value="12.8" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 8 (n=86,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="4.12"/>
                    <measurement group_id="O2" value="12.8" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 9 (n=74,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="3.80"/>
                    <measurement group_id="O2" value="12.7" spread="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 10 (n=65,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="3.49"/>
                    <measurement group_id="O2" value="12.3" spread="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 11 (n=56,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="3.83"/>
                    <measurement group_id="O2" value="12.0" spread="4.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in BCVA in the Study Eye</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline, Up to 4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BCVA in the Study Eye</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). A positive change from Baseline indicates improvement.</description>
          <population>All participants with data available.</population>
          <units>lines</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=133,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="4.04"/>
                    <measurement group_id="O2" value="11.8" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 2(n=116,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="3.12"/>
                    <measurement group_id="O2" value="1.0" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 3 (n=115,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="3.33"/>
                    <measurement group_id="O2" value="1.3" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 4 (n=118,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="3.37"/>
                    <measurement group_id="O2" value="1.1" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 5 (n=109,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="4.02"/>
                    <measurement group_id="O2" value="1.3" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 6 (n=101,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="4.18"/>
                    <measurement group_id="O2" value="1.2" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 7 (n=89,69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="4.04"/>
                    <measurement group_id="O2" value="1.1" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 8 (n=73,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="4.32"/>
                    <measurement group_id="O2" value="0.8" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 9 (n=66,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="4.00"/>
                    <measurement group_id="O2" value="1.5" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 10 (n=58,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="3.96"/>
                    <measurement group_id="O2" value="1.3" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 11 (n=49,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="4.21"/>
                    <measurement group_id="O2" value="0.4" spread="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Increase From Baseline of ≥2 Lines in BCVA in the Study Eye</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). An increase of 2 or more lines read correctly from Baseline indicates improvement.</description>
        <time_frame>Baseline, Up to 4 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Increase From Baseline of ≥2 Lines in BCVA in the Study Eye</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). An increase of 2 or more lines read correctly from Baseline indicates improvement.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Time of Injection 2 (n=139,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.29"/>
                    <measurement group_id="O2" value="30.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 3 (n=141,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.43"/>
                    <measurement group_id="O2" value="35.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 4 (n=141,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.43"/>
                    <measurement group_id="O2" value="29.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 5 (n=134,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.30"/>
                    <measurement group_id="O2" value="32.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 6 (n=120,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.83"/>
                    <measurement group_id="O2" value="25.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 7 (n=107,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.73"/>
                    <measurement group_id="O2" value="35.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 8 (n=86,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.51"/>
                    <measurement group_id="O2" value="28.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 9 (n=74,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                    <measurement group_id="O2" value="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 10 (n=65,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.69"/>
                    <measurement group_id="O2" value="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 11 (n=56,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.07"/>
                    <measurement group_id="O2" value="21.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Increase From Baseline of ≥3 Lines in BCVA in the Study Eye</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). An increase of 3 or more lines read correctly from Baseline indicates improvement.</description>
        <time_frame>Baseline, Up to 4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Increase From Baseline of ≥3 Lines in BCVA in the Study Eye</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). An increase of 3 or more lines read correctly from Baseline indicates improvement.</description>
          <population>All participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Time of Injection 2 (n=139,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.90"/>
                    <measurement group_id="O2" value="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 3 (n=141,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.37"/>
                    <measurement group_id="O2" value="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 4 (n=141,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.53"/>
                    <measurement group_id="O2" value="17.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 5 (n=134,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.09"/>
                    <measurement group_id="O2" value="20.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 6 (n=120,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.83"/>
                    <measurement group_id="O2" value="19.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 7 (n=107,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.45"/>
                    <measurement group_id="O2" value="21.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 8 (n=86,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.23"/>
                    <measurement group_id="O2" value="22.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 9 (n=74,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.54"/>
                    <measurement group_id="O2" value="28.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 10 (n=65,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.00"/>
                    <measurement group_id="O2" value="28.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 11 (n=56,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.71"/>
                    <measurement group_id="O2" value="17.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CRT by OCT in the Study Eye</title>
        <description>CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline, Up to 4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CRT by OCT in the Study Eye</title>
          <description>CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation. A negative change from Baseline indicates improvement.</description>
          <population>All participants with data available.</population>
          <units>µm (microns)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=128,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="499.1" spread="188.14"/>
                    <measurement group_id="O2" value="413.4" spread="104.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 2 (n=110,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-159.5" spread="183.98"/>
                    <measurement group_id="O2" value="-44.7" spread="93.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 3 (n=110,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-158.6" spread="188.06"/>
                    <measurement group_id="O2" value="-62.1" spread="100.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection4 (n=117,104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-151.9" spread="204.10"/>
                    <measurement group_id="O2" value="-66.8" spread="102.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 5 (n=109,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-169.4" spread="211.28"/>
                    <measurement group_id="O2" value="-55.7" spread="82.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 6 (n=93,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-180.8" spread="223.14"/>
                    <measurement group_id="O2" value="-63.0" spread="89.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 7 (n=85,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-171.5" spread="225.49"/>
                    <measurement group_id="O2" value="-70.1" spread="97.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 8 (n=70,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-202.7" spread="191.62"/>
                    <measurement group_id="O2" value="-82.5" spread="103.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 9 (n=63,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-224.2" spread="186.64"/>
                    <measurement group_id="O2" value="-66.4" spread="108.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 10 (n=65,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-210.0" spread="226.05"/>
                    <measurement group_id="O2" value="-60.9" spread="105.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Up to Injection 11 (n=48,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-212.4" spread="207.39"/>
                    <measurement group_id="O2" value="-76.0" spread="119.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement of ≥2 Lines in BCVA in the Study Eye</title>
        <description>Kaplan-Meier estimates of the time in months to improvement of ≥2 lines in BCVA. BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best).</description>
        <time_frame>4 Years</time_frame>
        <population>All participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement of ≥2 Lines in BCVA in the Study Eye</title>
          <description>Kaplan-Meier estimates of the time in months to improvement of ≥2 lines in BCVA. BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best).</description>
          <population>All participants with available data.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6667" lower_limit="0.0000" upper_limit="44.6333"/>
                    <measurement group_id="O2" value="7.1500" lower_limit="0.0000" upper_limit="45.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement of ≥3 Lines in BCVA in the Study Eye</title>
        <description>Kaplan-Meier estimates of the time in months to improvement of ≥3 lines in BCVA. BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best).</description>
        <time_frame>4 Years</time_frame>
        <population>All participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement of ≥3 Lines in BCVA in the Study Eye</title>
          <description>Kaplan-Meier estimates of the time in months to improvement of ≥3 lines in BCVA. BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best).</description>
          <population>All participants with available data.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2167" lower_limit="0.0000" upper_limit="44.6333"/>
                    <measurement group_id="O2" value="9.1000" lower_limit="0.233" upper_limit="843.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement in BCVA to 20/40 or Better in the Study Eye</title>
        <description>Kaplan-Meier estimates of the time to Improvement in months in BCVA to 20/40 or Better. BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly.</description>
        <time_frame>4 Years</time_frame>
        <population>All participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement in BCVA to 20/40 or Better in the Study Eye</title>
          <description>Kaplan-Meier estimates of the time to Improvement in months in BCVA to 20/40 or Better. BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly.</description>
          <population>All participants with available data.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3167" lower_limit="0.0667" upper_limit="44.6333"/>
                    <measurement group_id="O2" value="3.3667" lower_limit="0.000" upper_limit="843.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</title>
        <description>Kaplan-Meier estimates of the time to improvement in months in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>4 Years</time_frame>
        <population>All participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</title>
          <description>Kaplan-Meier estimates of the time to improvement in months in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with available data.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5333" lower_limit="0.2333" upper_limit="45.7333"/>
                    <measurement group_id="O2" value="7.9333" lower_limit="0.233" upper_limit="854.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement to Both 20/40 or Better in BCVA and Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</title>
        <description>Kaplan-Meier estimates of the time to improvement to Both 20/40 or Better in BCVA and Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT. BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
        <time_frame>4 Years</time_frame>
        <population>All participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement to Both 20/40 or Better in BCVA and Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</title>
          <description>Kaplan-Meier estimates of the time to improvement to Both 20/40 or Better in BCVA and Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT. BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.</description>
          <population>All participants with available data.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6167" lower_limit="0.2333" upper_limit="45.7333"/>
                    <measurement group_id="O2" value="9.8000" lower_limit="0.233" upper_limit="854.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Between Anti-VEGF Injections in the Study Eye</title>
        <description>The mean time in months between anti-VEGF Injections.</description>
        <time_frame>4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Between Anti-VEGF Injections in the Study Eye</title>
          <description>The mean time in months between anti-VEGF Injections.</description>
          <population>All participants with data available.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Time of Injection 2 (n=163,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.57"/>
                    <measurement group_id="O2" value="1.5" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 3 (n=162,154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.60"/>
                    <measurement group_id="O2" value="1.6" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 4 (n=157,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.10"/>
                    <measurement group_id="O2" value="1.7" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 5 (n=143,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.73"/>
                    <measurement group_id="O2" value="1.4" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 6 (n=127,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.19"/>
                    <measurement group_id="O2" value="1.3" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 7 (n=114,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.70"/>
                    <measurement group_id="O2" value="1.5" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 8 (n=99,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="3.11"/>
                    <measurement group_id="O2" value="1.3" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 9 (n=82,52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.78"/>
                    <measurement group_id="O2" value="1.4" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 10 (n=73,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.57"/>
                    <measurement group_id="O2" value="1.2" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 11 (n=63,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.53"/>
                    <measurement group_id="O2" value="1.2" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Intravitreal Anti-VEGF Injections in the Study Eye</title>
        <description>To be included in the time period analysis, patients must have been enrolled on the study for at least a minimum of 0 weeks, 24 weeks, 50 weeks, 100 weeks, and 150 weeks, respectively, and must have received at least 1 injection during that time period.</description>
        <time_frame>0-6 Months, 7-12 Months, Years 1,2,3</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Intravitreal Anti-VEGF Injections in the Study Eye</title>
          <description>To be included in the time period analysis, patients must have been enrolled on the study for at least a minimum of 0 weeks, 24 weeks, 50 weeks, 100 weeks, and 150 weeks, respectively, and must have received at least 1 injection during that time period.</description>
          <population>All participants with data available.</population>
          <units>injections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-6 Months (n = 158,149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.40"/>
                    <measurement group_id="O2" value="4.0" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7-12 Months (n = 99,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.64"/>
                    <measurement group_id="O2" value="2.8" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1 (n = 117,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="2.90"/>
                    <measurement group_id="O2" value="5.8" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2 (n = 40,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="2.98"/>
                    <measurement group_id="O2" value="5.0" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3 (n = 17,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="2.99"/>
                    <measurement group_id="O2" value="3.4" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Switching to a Second or Third Anti-VEGF Agent After First Injection in the Study Eye</title>
        <time_frame>UP to 4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Switching to a Second or Third Anti-VEGF Agent After First Injection in the Study Eye</title>
          <population>All participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33"/>
                    <measurement group_id="O2" value="47.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Switching Among Different Anti-VEGF Agents in the Study Eye</title>
        <description>Participants who switched among the different Anti-VEGF Agents: bevacizumab, ranibizumab and aflibercept.</description>
        <time_frame>Up to 4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Switching Among Different Anti-VEGF Agents in the Study Eye</title>
          <description>Participants who switched among the different Anti-VEGF Agents: bevacizumab, ranibizumab and aflibercept.</description>
          <population>All participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>bevacizumab to aflibercept</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bevacizumab to ranibizumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33"/>
                    <measurement group_id="O2" value="25.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aflibercept to bevacizumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aflibercept to ranibizumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00"/>
                    <measurement group_id="O2" value="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ranibizumab to bevacizumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.33"/>
                    <measurement group_id="O2" value="73.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ranibizumab to aflibercept</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Undergoing Focal Laser Surgery in the Study Eye</title>
        <time_frame>4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Undergoing Focal Laser Surgery in the Study Eye</title>
          <population>All participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00"/>
                    <measurement group_id="O2" value="44.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Undergoing Panretinal Photocoagulation (PRP) Surgery in the Study Eye</title>
        <time_frame>4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Undergoing Panretinal Photocoagulation (PRP) Surgery in the Study Eye</title>
          <population>All participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.45"/>
                    <measurement group_id="O2" value="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Loss (Decrease) in BCVA of ≥1 Line From Baseline in the Study Eye</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). A loss of 1 or more lines read correctly from Baseline indicates a worsening of vision.</description>
        <time_frame>Baseline, Up to 4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Loss (Decrease) in BCVA of ≥1 Line From Baseline in the Study Eye</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). A loss of 1 or more lines read correctly from Baseline indicates a worsening of vision.</description>
          <population>All participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Time of Injection 2 (n=139,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.67"/>
                    <measurement group_id="O2" value="15.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 3 (n=141,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.18"/>
                    <measurement group_id="O2" value="21.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 4 (n=141,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.57"/>
                    <measurement group_id="O2" value="23.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 5 (n=134,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.15"/>
                    <measurement group_id="O2" value="15.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 6 (n=120,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.50"/>
                    <measurement group_id="O2" value="19.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 7 (n=107,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.69"/>
                    <measurement group_id="O2" value="18.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 8 (n=86,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.28"/>
                    <measurement group_id="O2" value="22.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 9 (n=74,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.86"/>
                    <measurement group_id="O2" value="17.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 10 (n=65,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.54"/>
                    <measurement group_id="O2" value="20.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 11 (n=56,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.21"/>
                    <measurement group_id="O2" value="13.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Gain (Increase) in BCVA of ≥1 Line From Baseline in the Study Eye</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). A gain of 1 or more lines read correctly from Baseline indicates an improvement of vision.</description>
        <time_frame>Baseline, Up to 4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Gain (Increase) in BCVA of ≥1 Line From Baseline in the Study Eye</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). A gain of 1 or more lines read correctly from Baseline indicates an improvement of vision.</description>
          <population>All participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Time of Injection 2 (n=139,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.99"/>
                    <measurement group_id="O2" value="45.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 3 (n=141,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.70"/>
                    <measurement group_id="O2" value="53.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 4 (n=141,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.32"/>
                    <measurement group_id="O2" value="47.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 5 (n=134,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.73"/>
                    <measurement group_id="O2" value="50.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 6 (n=120,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.83"/>
                    <measurement group_id="O2" value="44.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 7 (n=107,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.88"/>
                    <measurement group_id="O2" value="45.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 8 (n=86,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.65"/>
                    <measurement group_id="O2" value="45.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 9 (n=74,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.46"/>
                    <measurement group_id="O2" value="44.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 10 (n=65,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00"/>
                    <measurement group_id="O2" value="41.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 11 (n=56,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.36"/>
                    <measurement group_id="O2" value="39.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With No Change in BCVA From Baseline in the Study Eye</title>
        <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best).</description>
        <time_frame>Baseline, Up to 4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With No Change in BCVA From Baseline in the Study Eye</title>
          <description>BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best).</description>
          <population>All participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Time of Injection 2 (n=139,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.99"/>
                    <measurement group_id="O2" value="34.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 3 (n=141,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.89"/>
                    <measurement group_id="O2" value="19.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 4 (n=141,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.31"/>
                    <measurement group_id="O2" value="25.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 5 (n=134,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.16"/>
                    <measurement group_id="O2" value="24.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 6 (n=120,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67"/>
                    <measurement group_id="O2" value="23.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 7 (n=107,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.15"/>
                    <measurement group_id="O2" value="30.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 8 (n=86,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.60"/>
                    <measurement group_id="O2" value="18.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 9 (n=74,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.92"/>
                    <measurement group_id="O2" value="31.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 10 (n=65,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.85"/>
                    <measurement group_id="O2" value="30.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to Time of Injection 11 (n=56,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.07"/>
                    <measurement group_id="O2" value="21.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Undergoing Glaucoma Laser Surgery in the Study Eye</title>
        <time_frame>4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Undergoing Glaucoma Laser Surgery in the Study Eye</title>
          <population>All participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61"/>
                    <measurement group_id="O2" value="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Undergoing Incisional Glaucoma Surgery in the Study Eye</title>
        <time_frame>4 Years</time_frame>
        <population>All participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Undergoing Incisional Glaucoma Surgery in the Study Eye</title>
          <population>All participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Phakic Patients With Cataract Surgery in the Study Eye</title>
        <description>Phakic patients have intraocular lens implants.</description>
        <time_frame>4 Years</time_frame>
        <population>All phakic participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With RVO</title>
            <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
          <group group_id="O2">
            <title>Patients With DME</title>
            <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Phakic Patients With Cataract Surgery in the Study Eye</title>
          <description>Phakic patients have intraocular lens implants.</description>
          <population>All phakic participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0"/>
                    <measurement group_id="O2" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 4 Years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients With RVO</title>
          <description>Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
        </group>
        <group group_id="E2">
          <title>Patients With DME</title>
          <description>Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Unknown heart complications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Hositalized for heart problems</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment OS (left eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Spots of blurred vision in left eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperallergic reaction to iron</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Methicilin-resistant staphylococcus aureus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Soft tissue mass cancer right leg</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Patient was hospitalized for dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid in lungs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Hospitalized for lack of oxygen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pacemaker placed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Medical Affairs,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

